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Abstract
Background—Influenza A virus (IAV) infection is a common respiratory tract infection that 
causes considerable morbidity and mortality worldwide.
Objective—To investigate the effect of a genetic deficiency of tissue factor (TF) in a mouse 
model of influenza A infection.
Methods—Wild-type mice, low tissue factor (LTF) mice and mice with the TF gene deleted in 
different cell types were infected with a mouse-adapted A/Puerto Rico/8/34 H1N1 strain of IAV. 
TF expression was measured in the lungs, and bronchoalveolar lavage fluid (BALF) was collected 
to measure extracellular vesicle TF, activation of coagulation, alveolar hemorrhage and 
inflammation.
Results—IAV infection of wild-type mice increased lung TF expression, activation of 
coagulation and inflammation in the BALF, but also led to alveolar hemorrhage. LTF mice and 
mice with a selective deficiency of TF in lung epithelial cells had low basal levels of TF and failed 
to increase TF expression after infection; these two strains of mice had more alveolar hemorrhage 
and death compared with controls. In contrast, deletion of TF in either myeloid cells or endothelial 
cells and hematopoietic cells did not increase alveolar hemorrhage or death after IAV infection. 
These results indicate that TF expression in the lung, particularly in epithelial cells, is required to 
maintain alveolar hemostasis after IAV infection.
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Conclusion—Our study indicates that TF-dependent activation of coagulation is required to 
limit alveolar hemorrhage and death after influenza A infection.
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Introduction
Influenza A virus (IAV) infection is a common cause of respiratory tract infection 
worldwide resulting in considerable mortality every year, especially in the elderly.(1) Viral 
infections in general are often associated with activation of the coagulation system as part of 
the innate immune response.(2–8) In mouse models of lethal IAV subtype H1N1 infection 
there is both pulmonary and systemic activation of coagulation.(9–11) In humans, acute IAV 
infection is associated with an increase in the incidence of thrombosis-related cardiovascular 
events, such as myocardial infarction and stroke.(12) Despite the activation of the 
coagulation system in the airspace, alveolar hemorrhages are observed in patients with IAV 
pneumonia and in lungs of H1N1 IAV-infected mice.(13–15)
Tissue factor (TF) plays an essential role in hemostasis but aberrant expression can 
contribute to thrombosis.(16) TF expression is induced in different cell types after viral 
infections. For instance, TF is induced in monocytes in HIV patients, is induced in 
circulating blood cells in monkeys infected with Ebola, and is induced in endothelial cells 
infected with herpes simplex virus or Dengue virus.(3–5, 8, 17, 18) Importantly, inhibition 
of the TF/FVIIa complex reduced mortality in a monkey model of Ebola hemorrhagic fever.
(17) Therefore, the prevailing view is that TF contributes to the pathology of viral infections.
TF is expressed in a tissue-specific manner.(19) We have proposed that TF expression in the 
lung is required to maintain hemostasis in this vital organ.(19) It is expressed by a variety of 
cell types, including bronchiolar, bronchial and alveolar epithelial cells, alveolar 
macrophages and fibroblasts.(20–25) Low TF [LTF] mice express ~1% levels of TF (26) and 
when crossed more than 6 generations onto a C57Bl/6 background exhibit spontaneous 
hemorrhages in their lungs.(27) Moreover, we found that intra-tracheal instillation of LPS 
into the lungs of LTF mice increased levels of cell-free hemoglobin in bronchoalveolar 
lavage fluid (BALF), which indicated alveolar hemorrhage.(25) Finally, Tf+/− mice have 
decreased levels of the coagulation activation marker thrombin-antithrombin complexes 
(TATc) in BALF after ventilator-induced acute lung injury (ALI).(28) These results 
demonstrate that TF plays a central role in lung hemostasis under basal conditions and after 
lung injury.
TF also contributes to lung pathology. Indeed, excessive TF-dependent activation of 
coagulation leads to intra-alveolar fibrin deposition associated with endotoxemia and sepsis.
(29) In a mouse endotoxemia model, we observed increased total Tf mRNA expression in 
the lung and increased expression in alveolar epithelial cells but not bronchiolar epithelial 
cells.(20, 30) Similarly, Drake and colleagues found increased TF protein expression in 
alveolar epithelial cells in the lungs of septic baboons.(23) BALF from healthy individuals 
contains TF activity in small membrane vesicles called extracellular vesicles (EVs).(31) In 
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addition, patients with acute respiratory distress syndrome (ARDS) or ALI have increased 
TF expression in alveolar epithelial cells and alveolar macrophages.(24) Interestingly, EV 
TF activity is increased in the airspace in patients with ALI/ARDS and appears to originate 
from alveolar epithelium.(24, 32, 33) Finally, LPS stimulation of alveolar macrophages 
increases TF expression.(34)
In this study, we used a genetic approach to examine the role of TF-dependent activation of 
coagulation on alveolar hemorrhage and survival in mice after IAV infection.
Material and Methods
We used the mouse-adapted strain of influenza A/Puerto Rico/8/1934 (H1N1, PR/8) (ATCC, 
Manassas, VA). The virus was propagated in 10–12 day old embryonated chicken eggs and 
purified as described previously.(7) Viral titers were determined using a hemagglutination 
assay.(7) For virus inoculation, mice were anesthetized with isoflurane and infected intra-
nasally with IAV at the dose of 0.02 hemagglutination units (HAU) in 50 µL PBS. Lungs and 
BALF were collected at various times after infection. Mice were euthanized if they had 
≥25% loss of initial body weight as instructed by our animal protocol.
Mice
We used male wild-type (WT) C57Bl/6, LTF mice and mice with deletion of the TF gene on 
different cell types. LTF mice have been described (26, 27). Tffl/fl mice were crossed with 
mice expressing the Cre recombinase in different cell types to generate mice with cell type-
specific deletion of the TF gene.(35) Mice with the TF gene deleted in myeloid cells using 
the lysosomal M promoter (Tffl/fl,LysM-Cre) have been described and will be referred as 
TFΔMy mice.(36) We used the Tie2 promoter to delete the TF gene in both endothelial cells 
and hematopoietic cells (Tffl/fl,Tie2-Cre) and will refer to these mice as TFΔEc.(36) Mice 
with the TF gene deleted in lung epithelial cells using the surfactant protein C promoter 
(Tffl/fl,SPC-Cre) have been described and will be referred to as TFΔEp mice.(37) We used 
Tffl/fl littermates as controls. We also used factor IX (FIX) null mice.(38) All mice were 
backcrossed onto the C57Bl/6 background and were 8–10 weeks of age. All experimental 
protocols were approved by the University of North Carolina-Chapel Hill's Institutional 
Animal Care and Use Committee.
Bronchoalveolar lavage
Mice were euthanized by cervical dislocation under isoflurane anesthesia after the terminal 
blood draw, and then BALF or tissue samples were prepared from non-perfused lungs as 
described below. BALF was collected from infected and uninfected mice by postmortem 
lavage using 3 × 900 µL of ice-cold PBS.(7) BALF were centrifuged (500 × g, 20 minutes, 
4°C), and the supernatant and cell pellets separated. Cell pellets were re-suspended in 200 
µL of PBS. WBC and hemoglobin levels in re-suspended cell pellets were determined using 
a Hemavet 950 (Drew Scientific, Miami Lakes, FL).
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Paraffin-embedded lung sections were de-paraffinized with antigen retrieval by standard 
procedures. Slides were blocked by 2% normal rabbit serum (Vector Lab, Burlingame, CA) 
in 0.4% triton X-100/PBS for 15 min at room temperature. Then, slides were incubated 
overnight at 4°C with 1 µg/mL anti-human TF goat polyclonal antibody (R&D Systems, 
Minneapolis, MN), rinsed and incubated with 1.5 µg/mL biotinylated rabbit anti-goat 
secondary antibody (Vector Lab) for 20 min at room temperature. Slides were developed 
color with DAB (Vector Lab) for 1 min and counterstained with hematoxylin (Thermo 
Fisher Scientific, Waltham, MA) for 1 min.(39)
RNA isolation and RT-PCR
Total lung RNA was isolated by TRIzol method (Life Technologies, Carlsbad, CA).(40, 41) 
One microgram of RNA was reverse transcribed into cDNA using the iScript™ RT 
Supermix (Bio-Rad Laboratories, Hercules, CA). The levels of H1N1 PR/8 genomes and TF 
mRNA were measured by real-time PCR using SSoFast™ Probes Supermix (Bio-Rad) in a 
realplex2 Mastercycler (Eppendorf, Hamburg, Germany) as described.(7) The housekeeping 
gene Rpl4 was used to correct for variations in input RNA and reaction efficiency.(42) Real-
time PCR primer/probes for H1N1 PR/8, murine Tf, and murine Rpl4 were purchased from 
Integrated DNA Technologies (Coralville, IA): H1N1 PR/8 forward, 5'-
GGACTGCAGCGTAGACGCTT-3'; H1N1 PR/8 reverse, 5'-
CATCCTGTTGTATATGAGGCCCAT-3'; H1N1 PR/8 probe, 5'-/56-FAM/
CTCAGTTATTCTGCTGGTGCACTTGCCA/36-TAMSp/-3'; Tf forward, 5'-
TTTGGCAAGGACTTGGGTTA-3'; Tf reverse, 5'-GCTTACTCCTTCTTCCACATCA-3'; Tf 
probe, 5'-/56-FAM/CCGTGCTTG/ZEN/AGCCTTTCCGATAAGT/3IABkFQ/-3'; Rpl4 
forward, 5'-TGGTGGTTGAAGATAAGGTTGA-3'; Rpl4 reverse, 5'-
CTTGCCAGCTCTCATTCTCTG-3'; Rpl4 probe, 5'-/56-FAM/CTGAACAGC/ZEN/
CTCCTTGGTCTTCTTGTA/3IABkFQ/-3'.
Measurement of TF activity
For measurement of TF activity, lung tissues were homogenized in 15 mM n-Octyl-β-D-
glucopyranoside in 25 mM HEPES/saline buffer at the volume of 1.5 mL per 10 mg of 
tissue. Samples were incubated at 37°C for 15 minutes.(26, 35) Homogenized samples were 
diluted 20 times with 25 mM HEPES/saline buffer. For measurement of TF activity in the 
BALF cells, cell pellets were homogenized in 200 µL of 15 mM n-Octyl-β-D-
glucopyranoside in 25 mM HEPES/saline buffer. The homogenized samples were diluted 5 
times with 25 mM HEPES/saline buffer. Twenty-five µL of the diluted samples were mixed 
with an equal amount of pooled normal mouse plasma and 20 mM CaCl2 and the clotting 
time was determined using a STart4 coagulation analyzer. EV TF activity was measured 
from 10 µL of BALF supernatant as described.(43) Serially diluted recombinant human TF 
(Innovin, Dade Behring) was used to generate a standard curve. TF activity was normalized 
to the protein concentration obtained by BCA assay as described.(7)
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Measurement of TATc and cytokines/chemokines
Levels of TATc in BALF supernatant were quantified by ELISA (TAT Enzygnost Micro Kit; 
Dade Behring, Deerfield, IL).(7, 36) The level of various cytokines/chemokines in the BALF 
supernatant was measured using commercial ELISAs (Duo-Set, R&D Systems, 
Minneapolis, MN).(7)
Statistics
All statistical analyses were performed using either GraphPad Prism (version 5.0; GraphPad 
Software Inc., La Jolla, CA). Data are represented as mean ± SEM. For 2-group comparison 
of continuous data, 2-tailed Student’s t test was used. For multiple-group comparison, data 
were analyzed by 1- or 2-way ANOVA and were Bonferroni corrected for repeated measures 
over time. A P value less than 0.05 was considered significant.
Results
Influenza A virus infection of mice increases TF expression, activation of coagulation, 
alveolar hemorrhage and inflammation
To determine the effect of IAV infection on TF expression in the lung, WT mice were 
infected with IAV and lung and BALF samples were collected at 0, 1, 3, 4, 7 and 14 days 
post infection (dpi). We detected IAV genomes in the lungs at 3, 4 and 7 days (Figure 1A). 
We measured lung TF activity as well as EV TF activity and TATc as a marker of the 
activation of coagulation in BALF. IAV infection led to a time-dependent increase in lung 
TF activity and EV TF activity with maximal levels 4 dpi (Figure 1B and C). IAV infection 
also increased TATc in the BALF at 4, 7 and 14 dpi (Figure 1D). We measured levels of 
hemoglobin in the BALF as a marker of alveolar hemorrhage. Levels of hemoglobin 
increased in a time-dependent manner with maximal levels at 7 dpi (Figure 1E). Levels of 
WBC in the BALF also increased after infection (Figure 1F). We measured levels of 
different cytokines/chemokines in the BALF of mice before and 7 dpi. IAV infection 
significantly increased IL-1β and Ccl2 (Figure 1G and H), and Ccl5 (37.6±14.9 pg/mL vs. 
327.3 ± 25.7 pg/mL, N=4, P<0.05) and Cxcl10 (0±0.0 pg/mL vs. 5882.7±255.5 pg/mL, 
N=4, P<0.05) but not TNF-α or Cxcl2 (data not shown). These data indicate that IAV 
infection of WT mice increases TF expression, activation of coagulation, alveolar 
hemorrhage and inflammation.
Influenza A infection increases TF expression in lung epithelial cells
We examined the effect of a global deficiency of TF on the induction of TF and activation of 
coagulation after IAV infection. LTF mice had significantly lower basal levels of lung TF 
activity than control mice (Figure 2A). In addition, we did not observe any increase in lung 
TF activity after IAV infection in LTF mice (Figure 2A). Levels of EV TF activity in BALF 
were also significantly lower in LTF mice after IAV infection compared with controls 
(Figure 2B). As expected, IAV-infected LTF mice had significantly lower levels of TATc in 
the BALF compared with IAV-infected control mice (Figure 2C).
To examine the contribution of lung epithelial cell TF to total TF expression in the lung and 
activation of coagulation after IAV infection, we used TFΔEp mice that have a selective 
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deletion of the TF gene in lung epithelial cells. We recently showed that these mice have 
lower basal levels of lung TF compared with controls.(37) Uninfected TFΔEp mice had 
significantly lower levels of lung TF mRNA and activity compared to Tffl/fl littermate 
controls (Figure 2D and E). Importantly, we did not observe any increase in lung TF mRNA 
or activity in TFΔEp mice after IAV infection (Figure 2D and E). Moreover, there were 
significantly lower levels of EV TF activity in BALF in TFΔEp mice compared with controls 
(Figure 2F). TFΔEp mice also had lower levels of TATc in the BALF compared with control 
mice but the difference was not statistically significant (Figure 2G). Next, we analyzed 
TFΔMy mice to examine the role of myeloid cell TF in IAV infection. We have shown that 
levels of TF are significantly decreased in circulating myeloid cells in these mice.(36) 
Deletion of TF in myeloid cells did not affect TF expression in the lung or EVs in the BALF, 
or activation of coagulation after IAV infection (Figure 2H–K). Similar results were 
observed with TFΔEc mice that have a deficiency of TF in endothelial cells and 
hematopoietic cells (data not shown).
We analyzed TF protein in the lung of uninfected and IAV infected mice by 
immunohistochemistry. In uninfected WT mice we observed strong TF signal in adventitial 
cells surrounding larger blood vessels and in bronchial epithelial cells as well as weaker 
signal in alveolar epithelial cells (Figure 3B and E). The TF signal was increased in all cell 
types after IAV infection (Figure 3C and F). We did not observe TF signal in endothelial or 
blood cells. In IAV infected TFΔEp mice, we observed TF antigen in adventitial cells 
surrounding blood vessel but no signal in bronchial epithelial cells and alveolar epithelial 
cells (Figure 3G–I). Interestingly, adventitial cells surrounding bronchioles expressed TF in 
TFΔEp mice (Figure 3H). These results indicate that lung epithelial cells are a major source 
of basal TF expression in the lung and are the primary source of inducible TF in the lungs of 
IAV infected mice.
Reduced TF expression leads to increased alveolar hemorrhage in mice after influenza A 
virus infection
We determined the role of TF in maintaining lung hemostasis in mice after IAV infection. 
We assessed alveolar hemorrhage by measuring the level of hemoglobin in BALF. There 
were no signs of alveolar hemorrhage in uninfected mice. However, BALF from IAV-
infected control mice was light pink and had increased levels of hemoglobin compared with 
uninfected mice at 7 dpi (Figure 4A–D). BALF of LTF mice was bright red and had a 
significantly higher level of hemoglobin compared with control mice at 7 dpi (Figure 4A). 
BALF of infected TFΔEp mice also had increased levels of hemoglobin in the BALF at 7 dpi 
compared with controls (Figure 4B). In contrast to the results with the LTF and TFΔEp 
mice, we did not observe an increase in alveolar hemorrhage in TFΔMy or TFΔEc mice 
(Figure 4C and D). Interestingly, FIX null mice did not exhibit increased alveolar 
hemorrhage after IAV infection (data not shown). These data indicate that either a global a 
deficiency of TF or a selective deficiency of TF in lung epithelial cells is associated with 
increased alveolar hemorrhage after IAV infection.
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A deficiency of TF does not affect inflammation or levels of virus
In an endotoxemia model LTF mice had significantly lower levels of IL-6 compared with 
controls.(44) Therefore, we determined if a deficiency of TF was associated with reduced 
expression of inflammatory mediators in the BALF at 7 dpi. Levels of IL-1β, Ccl5 and 
Cxcl10 were not significantly reduced in LTF mice after IAV infection but there was a 
significant increase in Ccl2 (Supplementary Figure 1A, C, E and G). We did not observe any 
differences in the expression of inflammatory mediators in TFΔEp mice (Supplementary 
Figure 1B, D, F and H). In addition, either a global deficiency of TF or cell type-specific 
deletion of TF did not affect the level of IAV genomes in the lungs 7 dpi (Supplementary 
Figure 2A–D).
Effect of TF deficiency on mortality of mice after influenza A virus infection
We used a dose of IAV that caused ~20% mortality in control mice. The body weight of 
control mice decreased after infection and then partially recovered by day 14. We analyzed 
the effect of either global deficiency in TF or deletion of the TF gene in different cell types 
on the mortality of mice after IAV infection. Infected LTF mice had a significantly higher 
mortality compared with infected control mice but surviving mice had similar weight 
changes as control mice (Figure 5A and B). Similarly, TFΔEp mice also exhibited an 
increase in mortality but no change in weight loss after infection compared to control mice 
(Figure 5C and D). TFΔMy and TFΔEc mice had a similar mortality and weight change as 
control mice (Figure 5E–H). FIX null mice exhibited similar survival to controls (data now 
shown). These results indicate that either a global deficiency of TF or a deletion of TF in 
epithelial cells is associated with increased mortality after IAV infection.
Discussion
Patients infected with IAV commonly have alveolar hemorrhage and this is a complication 
of influenza pneumonia particularly with the H1N1 strain.(13, 45–50) Importantly, 
retrospective studies showed an association between alveolar hemorrhages and increased 
mortality.(51, 52) Although alveolar hemorrhage is a feature of influenza pneumonia, the 
mechanisms of hemorrhage are unknown. Furthermore, it is unclear why severe alveolar 
hemorrhage is well described in influenza pneumonia but is a less common feature in other 
infectious pneumonias.(15) Our studies show that the lung epithelium, the very cells infected 
and killed by influenza infection, is the primary source of TF in the airspace. Importantly, 
either a global deficiency in TF or a genetic deficiency of TF in lung epithelial cells is 
associated with a significant increase in alveolar hemorrhage after IAV infection. These 
results indicate that lung epithelial TF helps limit alveolar hemorrhage in IAV pneumonia.
We found that IAV infection increases TF expression in the lungs of WT mice and this 
induction is abolished in mice with either a global deficiency in TF or a selective deficiency 
of TF in lung epithelial cells, but not in myeloid cells or endothelial cells and hematopoietic 
cells. Similarly, we recently found that induction of TF expression in the lung by intra-
tracheal LPS is abolished in these TFΔEp mice but not in mice with a deficiency of TF in 
myeloid cells.(37) These studies indicate that epithelial cells are a major source of basal TF 
expression and the primary source of induced TF expression in the lung. However, TFΔEp 
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mice had higher levels of TF than LTF mice suggesting that other cell types in the lung 
express TF, such as fibroblasts. Indeed, we observed TF expression in adventitial cells 
surround blood vessels and bronchioles in TFΔEp mice that are likely to be fibroblasts. We 
did not see any deteectableTF expression in endothelial or blood cells. The increase in TF 
expression in infected WT mice was associated with activation of coagulation in the BALF. 
This is consistent with a previous study showing that levels of TATc were increased in the 
BALF of mice 4 days after IAV infection.(11) A global deficiency of TF was associated with 
a significant reduction in TATc in the BALF, which indicated that TF regulates coagulation 
in the lung after IAV infection.
We observed a low level of alveolar hemorrhage in WT mice after IAV infection, which 
indicates that the infection represents a hemostatic challenge to the lung. This finding is 
consistent with other studies of IAV infection in mice.(9–11) Mice with either a global 
deficiency in TF or a selective deficiency of TF in lung epithelial cells, but not mice lacking 
TF in myeloid cells or endothelial cells and hematopoietic cells or FIX null mice, exhibited 
increased alveolar hemorrhage after IAV infection. Similarly, we found that LTF mice and 
TFΔEp mice exhibited increased alveolar hemorrhage after intra-tracheal LPS.(25, 37) LTF 
mice exhibited more alveolar hemorrhage than TFΔEp mice indicating that cell types in 
addition to epithelial cells, such as fibroblasts, contribute to lung hemostasis after lung 
injury.
We observed a significant increase in mortality in infected LTF mice compared with 
controls. Similarly, TFΔEp mice were more susceptible to IAV infection compared with 
controls but this phenotype was not as dramatic as the LTF mice. At present, we can only 
speculate about the reasons for the increased mortality in LTF and TFΔEp mice. Increased 
alveolar hemorrhage is likely to contribute to the increased death but a deficiency of TF may 
also impacts other processes, such as vascular permeability. Interestingly, a deficiency of TF 
was not associated with a reduction in inflammatory mediators. In fact, LTF mice had 
increased levels of Ccl2. Finally, a reduction of TF did not affect levels of IAV genomes at 7 
dpi.
Inhibition of TF using a monoclonal antibody has been shown to attenuate the coagulopathy, 
reduce ALI and decrease mortality in an Escherichia coli baboon model of septic shock.(53) 
Similarly, systemic inhibition of the TF/FVIIa complex with site-inactivated recombinant 
factor VIIa (FFR-FVIIa), which acts as a competitive inhibitor of FVIIa, attenuated the 
coagulopathy and reduced lung injury in an Escherichia coli baboon model of septic shock.
(54) These studies led to a clinical trial to determine if FFR-FVIIa would be beneficial in 
mechanically ventilated patients with ALI and ARDS. However, there were no beneficial 
effects of FFR-FVIIa on morbidity and clinical outcome but there was a trend towards an 
increased risk of serious bleeding and higher mortality with the higher dose of FFR-FVIIa.
(55, 56) These results support the notion that TF plays a critical role in lung hemostasis.
In summary, we demonstrate a critical protective role for TF in the lung in a clinically 
relevant model of severe influenza pneumonia. Our results suggest that impairment of 
hemostasis may contribute to the pathology associated with influenza A pneumonia.
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Non-standard abbreviations
ALI acute lung injury
ARDS acute respiratory distress syndrome
BALF bronchoalveolar lavage fluid
dpi days post infection
IAV influenza A virus
H1N1/PR8 hemagglutanin type 1 and neuraminadase type 1/Puerto Rico strain 8/34
HAU hemagglutination units
Hb hemoglobin
LTF low tissue factor
Rbc red blood cells
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Figure 1. Influenza A infection increases TF expression and inflammation in the mouse lung
Wild-type mice were infected with influenza A virus (IAV) and samples were collected 
before and 1, 3, 4, 7 and 14 days after infection. (A) IAV genome levels in the lungs were 
quantified by real-time PCR and normalized to Rpl4 mRNA levels. Data are shown relative 
to day 3. (B) TF activity levels in the lung were measured using a one-stage clotting assay. 
(C) TF activity levels of extracellular vesicles (EV) isolated from the bronchoalveolar lavage 
fluid (BALF) were measured using a two-stage FXa generation assay. (D) Levels of 
thrombin-antithrombin complexes (TATc) in the BALF. (E) Levels of hemoglobin (Hb) in 
the BALF. (F) Levels of white blood cells (WBCs) in the BALF after IAV infection. (G) 
Levels of IL-1β in the BALF after IAV infection. (H) Levels of Ccl2 in the BALF after IAV 
infection. Data (mean ± SEM; n = 3–13 per group) were analyzed by 1-way ANOVA. 
Statistical significances are shown as *P<0.05, **P<0.01 and ***P<0.001 versus day 0.
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Figure 2. Levels of TF expression in TF deficient mice before and after influenza A infection
(A–C) Low TF (LTF) mice, (D–G)TFfl/fl,SPC-Cre (TFΔEp) and (H–K) TFfl/fl,LysM-Cre 
(TFΔMy) mice and their respective control mice (referred as C) were infected with influenza 
A virus (IAV) and the lungs and bronchoalveolar lavage fluid (BALF) were collected. Levels 
of lung Tf mRNA (D and H) and TF activity (A, E and I), TF activity of BALF extracellular 
vesicles (EV) (B, F and J), and BALF thrombin-antithrombin complexes (TATc) (C, G and 
K) are shown. Controls are shown in white bars and experimental mice are shown in black 
(LTF), hatched (TFΔEp), or cross-hatched (TFΔMy) bars. Levels of Tf mRNA in the lungs 
were quantified by real-time PCR before and 4 days after IAV infection. Data were 
normalized to Rpl4 mRNA levels. Levels of the uninfected controls were set to 1. Data 
(mean ± SEM; n = 3–7 for day 0, n =3–10 for day 4, and n = 3–8 for day 7) were analyzed 
by 2-way ANOVA or Student’s t-test. Statistical significance is shown as *P<0.05, **P<0.01 
and ***P<0.001 between groups or #P<0.05, ##P<0.01 and ###P<0.001 versus uninfected 
control of the respective genotypes.
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Figure 3. Influenza A infection increases TF protein expression in the lung
We analyzed TF antigen expression in the lungs of uninfected (B, E) and infected (7 dpi) 
wild-type mice (C, F), and infected TFΔEp mice (G–I) by immunohistochemistry. Tissue 
sections were incubated with (B, C, E, F–I) or without (A and D) a goat anti-mouse TF 
polyclonal antibody. The black arrows indicate TF expression in the epithelium of bronchi 
(Bc). The arrowheads indicate TF staining in adventitial cells of blood vessels (Bv). The 
white arrow indicates TF expression in adventitial cells surrounding a bronchiole. Original 
magnification x200. Scale bar is 100 µm.
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Figure 4. Effect of genetic deficiency of TF on alveolar hemorrhage in mice after influenza A 
infection
(A) Low TF (LTF) mice, (B) Tffl/fl,SPC-Cre (TFΔEp), (C) Tffl/fl,LysM-Cre (TFΔMy) and 
(D) Tffl/fl,Tie2-Cre (TFΔEc) mice and their respective control mice (referred as C) were 
infected with influenza A virus (IAV), and the bronchoalveolar lavage fluid (BALF) was 
collected before and 7 days after infection. Gross appearance of BALF and levels of 
hemoglobin (Hb) in BALF before and after IAV infection are shown. Controls are shown as 
white bars and experimental mice are shown as black bars (LTF), hatched (TFΔEp), cross-
hatched (TFΔMy), or vertical-striped (TFΔEc) bars. Data (mean ± SEM; 3– 11) were 
analyzed by Student’s t-test. Statistical significance is shown as *P<0.05 between groups.
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Figure 5. Effect of a global or cell type-specific deficiency of TF on mortality of mice after 
influenza A infection
(A and B) Low TF (LTF), (C and D) Tffl/fl,SPC-Cre (TFΔEp), (E and F), Tffl/fl,LysM-Cre 
(TFΔMy) and (G and H) Tffl/fl,Tie2-Cre (TFΔEc) mice and their respective control mice 
(referred as C) were infected with influenza A virus (IAV) and observed for 14 days. 
Survival rates (A, C, E and G) and changes in body weights of infected mice (B, D, F and H) 
are shown. Body weights before infection were set to 100% and did not differ significantly 
between genotypes. Data (mean ± SEM; n = 9–10 for A and B, n = 17–30 for C and D, n = 
7–8 for E and F, and n = 14–24 for G and H) were analyzed by log-rank test (A, C, E and G) 
or by 2-way ANOVA (B, D, F and H). Statistical significance is shown as *P<0.05 and 
**P<0.01 between groups.
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